Jefferies Raises BioAge Labs to Buy, Points to BGE-102 as Key Value Driver
Jefferies upgraded BioAge Labs Inc to Buy from Hold and raised its price target to $62 from $9, highlighting the promise of BGE-102, an oral NLRP3 inhibitor. The firm pointed to Phase 1 results and an attractive balance sheet as reasons for the upgrade. BioAge has public offerings planned to bolster its cash position as it advances Phase 2a and oph…